Core Insights - Tourmaline Bio, Inc. has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board, enhancing its expertise in cardiovascular disease research [1][2] Company Overview - Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with immune and inflammatory diseases [5] - The company's lead asset is pacibekitug (TOUR006), a long-acting, fully-human anti-IL-6 monoclonal antibody with potential applications in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) [6] Dr. Paul M. Ridker's Contributions - Dr. Ridker is recognized for his significant contributions to understanding cardiovascular disease, particularly the role of inflammation in atherosclerosis [2][4] - His research has led to the first FDA-approved diagnostic test for vascular inflammation and has influenced international guidelines for ASCVD [2][3] - He has led over 15 major, multi-national, randomized clinical trials and has received continuous funding from the National Institutes of Health [3] Development of Pacibekitug - Pacibekitug has been studied in approximately 450 participants across six completed clinical trials, indicating a robust development pipeline [6] - The company is preparing for the Phase 2 TRANQUILITY trial results and future development of pacibekitug to address inflammation in cardiovascular diseases [2][4]
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker